Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents.
Aromatase (estrogen synthase) is the cytochrome P450 enzyme complex that converts C19 androgens to C18 estrogens. Aromatase activity has been demonstrated in breast tissue in vitro, and expression of aromatase is highest in or near breast tumor sites. Thus, local regulation of aromatase by both endogenous factors as well as exogenous medicinal agents will influence the levels of estrogen available for breast cancer growth. The prostaglandin E2 (PGE2) increases intracellular cAMP levels and stimulates estrogen biosynthesis, and our recent studies have shown a strong linear association between CYP19 expression and the sum of COX-1 and COX-2 expression in breast cancer specimens. PGE2 can bind to four receptor subtypes, EP1-EP4, which are coupled to different intracellular signaling pathways. In primary human breast stromal cell cultures, aromatase activity was significantly induced by PGE2, dexamethasone, and agonists for the EP1 and EP2 receptor subtypes. An EP1 antagonist, SC-19220, inhibited the induction of enzyme activity by PGE2 or 17-phenyltrinor-PGE2, an EP1 agonist. Sulprostone, an EP3 agonist, did not alter aromatase activity levels. Investigations are also underway on the regulation of aromatase by exogenous medicinal agents. Selective steroidal and nonsteroidal agents are effective in inhibiting breast tissue aromatase. The benzopyranone ring system is a molecular scaffold of considerable interest, and this scaffold is found in certain flavonoid natural products that have weak aromatase inhibitory activity. Our novel synthetic route for benzopyranones utilizes readily available salicylic acids and terminal alkynes as starting materials. The synthesis of flavones with diversity on the benzopyranone moiety and at the C-2 position occurs with good to excellent yields using these reaction conditions, resulting in an initial benzopyranone library of thirty compounds exhibiting enhanced and differential aromatase inhibition. Current medicinal chemistry efforts focus on diversifying the benzopyranone scaffold and utilizing combinatorial chemistry approaches to construct small benzopyranone libraries as potential aromatase inhibitors.
Brueggemeier
R W
RW
College of Pharmacy and OSU Comprehensive Cancer Center, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210-1291, USA. bruggemeir.1@osu.edu
Richards
J A
JA
Joomprabutra
S
S
Bhat
A S
AS
Whetstone
J L
JL
D001141:Aromatase / Q000378:metabolism*; D047072:Aromatase Inhibitors; D001578:Benzopyrans / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D001940:Breast / Q000187:drug effects / Q000201:enzymology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology; D002478:Cells, Cultured; D020650:Combinatorial Chemistry Techniques; D015232:Dinoprostone / Q000494:pharmacology; D015195:Drug Design; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D005260:Female; D006801:Humans; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors / Q000378:metabolism; D017154:Stromal Cells / Q000187:drug effects / Q000201:enzymology; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
D047072:Aromatase Inhibitors; D001578:Benzopyrans; D004791:Enzyme Inhibitors; D011982:Receptors, Prostaglandin; D001141:Aromatase; D015232:Dinoprostone